666P Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patients

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Annals of Oncology

Topics

Medicine

Cancer Oncology

Immunology

Internal Medicine

Cancer Research

Show all topics

DOI

10.1016/j.annonc.2024.08.732